Single Cell and Spatial Omics of Amyopathic Dermatomyositis Treated With Brepocitinib

Overview

About this study

The purpose of this study is to predict responses through the identification of unique biomarkers of DM utilizing bulk, single-cell and spatial RNA sequencing.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:  

  • Participation in IRB 24-005157.

Exclusion Criteria:

  • Unwilling to participate in exploratory study.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 6/24/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Aaron Mangold, M.D.

Open for enrollment

Contact information:

Brett Renner

(480) 301-9797

Renner.Brett@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20571231

Mayo Clinic Footer